医薬品調査レビュー：2023年

世界の乱用薬物 (DOA) 検査の市場規模は、2022年の52億米ドルから、予測期間中はCAGR 9.3%で推移し、2027年には81億米ドルに達すると予測されています。

世界のバイオエンジニアリングタンパク質医薬品の市場規模は、2022年の3,541億米ドルから、予測期間中はCAGR 8.0%で推移し、2027年には5,213億米ドルに達すると予測されています。

世界の疼痛管理薬およびデバイスの市場規模は、2023年の846億米ドルから、予測期間中のCAGR 5.4％で推移し、2028年末には1,099億米ドルに達すると予測されています。

医薬品市場は世界で最も大きな産業のひとつであり、絶えず成長を続けています。医薬品では、新薬の参入や既存薬の性能向上など、継続的な研究開発が行われています。しかし、新薬の市場参入には約12～13年かかる一方で、既存薬の市場は高騰し続けており、この状況から医薬品市場は成長し続けています。

研究開発は、特に細胞治療や遺伝子治療などの技術的・科学的進歩によって推進されており、医薬品市場の成長に重要な役割を果たしています。市場は厳しい規制・償還政策や研究開発費の高騰の影響を受けています。AIは、創薬、臨床試験、薬剤スクリーニング、個別化医療、サプライチェーン管理、規制遵守、ファーマコビジランス、マーケティングインサイトなど、医薬品の複数の分野で利用されており、極めて重要であると考えられています。生成AIツールは、面倒で時間のかかる作業を自動化することで、創薬を加速させるのに役立ちます。

当調査レビューは、BCC Researchが2023年に発行した抗肥満薬、乱用薬物検査、バイオエンジニアリングタンパク質医薬品、疼痛管理薬およびデバイスに関するレポートのハイライトと抜粋を含み、それぞれの市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析などをまとめています。

目次

第1章 序文

第2章 抗肥満薬の世界市場 (PHM281A)

• 抗肥満薬
• 市場概要
• 抗肥満薬の市場概要
• 成人の肥満と過体重の定義
• 肥満の増加
• 肥満が世界経済に与える影響
• 肥満に関する意識の向上
• 抗肥満薬の世界市場：タイプ別
• 処方薬
• 市販薬
• 抗肥満薬の世界市場：流通チャネル別
• 病院薬局
• 小売薬局
• オンライン薬局
• 抗肥満薬の世界市場：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域
• 抗肥満薬のESG開発
• 抗肥満薬業界におけるESGの重要性
• 抗肥満薬業界におけるESGの柱
• ESGの格付けと指標：データの理解
• 抗肥満薬業界におけるESG実践
• BCCによる総論

第3章 乱用薬物検査：各種技術と世界市場 (PHM013J)

• 乱用薬物検査の市場と技術の背景
• 概要
• 検査技術
• 単一検査と複数パラメータ検査
• DOAスクリーニング
• ポーターのファイブフォース分析
• 乱用薬物検査の市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会
• 乱用薬物検査の規制シナリオ
• 北米
• 南米
• 中米・カリブ海
• 欧州
• アジア太平洋
• 薬物乱用検査の世界市場：薬物タイプ別
• アルコール
• アンフェタミンとメタンフェタミン
• 大麻/マリファナ
• コカイン
• オピオイド
• その他
• 薬物乱用検査の世界市場：エンドユーザー別
• 薬物検査ラボ
• 病院
• 職場
• その他
• 薬物乱用検査の世界市場：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域

第4章 バイオエンジニアリングタンパク質医薬品の世界市場 (BIO009H)

• バイオエンジニアリングタンパク質医薬品
• 市場概要
• バイオエンジニアリングタンパク質医薬品の市場と技術の背景
• タンパク質医薬品の概要
• バイオエンジニアリングタンパク質医薬品
• バイオエンジニアリングタンパク質医薬品の製造技術
• 天然資源 (ヒト/動物) からの分画/抽出
• 微生物発酵とバイオリアクター
• トランスジェニック
• 哺乳類細胞培養
• バイオエンジニアリングタンパク質医薬品の市場力学
• 市場推進因子
• 市場の課題
• バイオエンジニアリングタンパク質医薬品市場の内訳：医薬品タイプ別
• 概要
• モノクローナル抗体 (mAbs)
• ペプチドホルモン
• ワクチン
• 融合タンパク質
• 血液因子
• ペプチド抗生物質
• サイトカイン
• 治療用酵素
• バイオエンジニアリングタンパク質医薬品市場の内訳：疾患別
• 概要
• バイオエンジニアリングタンパク質医薬品市場の内訳：地域別
• 北米市場の収益：医薬品タイプ別
• 欧州市場の収益：医薬品タイプ別
• 新興市場の収益：医薬品タイプ別
• バイオエンジニアリングタンパク質医薬品市場の規制面と新規承認
• 新規承認
• 市場における新たな動向/今後の技術
• 二重特異性抗体および多重特異性抗体
• バイオ医薬品業界の主な動向

第5章 疼痛管理薬およびデバイスの世界市場 (HLC026G)

• 疼痛管理薬とデバイス
• 市場概要
• 疼痛管理薬およびデバイス市場のハイライト
• 疼痛管理薬およびデバイスの市場概要
• 疼痛の歴史と疼痛の治療
• 疼痛の認識
• 疼痛の種類
• 疼痛の評価
• 疼痛の診断方法
• 疼痛の治療方法
• 疼痛管理薬とデバイスの市場力学
• 市場促進要因
• 市場抑制要因
• 市場の課題
• 疼痛管理薬およびデバイス市場の内訳：製品別
• 医薬品
• 疼痛管理デバイス
• 疼痛管理薬およびデバイス市場の内訳：用途別
• 筋骨格系疼痛
• 術後疼痛
• 神経障害性疼痛
• 癌性疼痛
• 片頭痛
• その他
• 疼痛管理薬およびデバイス市場の内訳：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域
• ESGの展開
• ESG：イントロダクション
• 疼痛管理薬およびデバイス業界における持続可能性：ESGの観点
• ケーススタディ
• BCCによる総論
• 疼痛管理薬とデバイスの新技術
• 概要
• オピオイド薬の技術進歩
• 非麻薬性医薬品の技術進歩
• 神経調節デバイスの技術進歩
• 輸液ポンプの技術進歩
• 疼痛管理の動向

第6章 付録

List of Tables

• Table 1 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
• Table 2 : Definitions of Adult Obesity and Overweight
• Table 3 : Number of People, Aged Over 5 Years, and Percentage of the Population With Overweight or Obesity, 2020-2035
• Table 4 : Global Obesity Trends for Children and Adolescents, Aged 5 to 19 Years, by Gender, 2020-2035
• Table 5 : Global Obesity Trends for Adults, Aged 20 Years and Above, by Gender, 2020-2035
• Table 6 : Global Economic Impact of High BMI (BMI >=25kg/m2), 2020-2035
• Table 7 : Global Market for Anti-obesity Drugs, by Drug Type, Through 2028
• Table 8 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
• Table 9 : Global Market for Anti-obesity Drugs, by Region, Through 2028
• Table 10 : ESG Ratings and Metrics of Anti-obesity Drugs
• Table 11 : Environmental Performance of Anti-obesity Drugs
• Table 12 : Social Performance of Anti-obesity Drugs
• Table 13 : Governance Performance of Anti-obesity Drugs
• Table 14 : ESG Rankings for Major Anti-obesity Drug Companies, 2023*
• Table 15 : Global Market for Drugs of Abuse Testing, by Region, Through 2027
• Table 16 : Cutoff Concentrations for Initial and Confirmatory Drug Tests in Urine
• Table 17 : Deaths from Tobacco, Alcohol and Drugs, Across Countries, 2019
• Table 18 : Commonly Abused Drugs
• Table 19 : Prevalence of Drug Use in General, Population Across Region, 2020
• Table 20 : Global Drug Seizure, by Drug Type, 2020
• Table 21 : U.S. Drug Testing Legislation, by State, 2017
• Table 22 : European Drug Testing Legislation, by Country
• Table 23 : Global Market for Drugs of Abuse Testing, by Region, Through 2027
• Table 24 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
• Table 25 : Characteristics of Large Molecule/Protein Drugs
• Table 26 : Bioengineered Protein Drugs vs. Chemically Synthesized Drugs
• Table 27 : Selected Protein Drugs Made, by Fractionation
• Table 28 : Selected Therapeutic Drugs Produced, by Microbial Fermentation
• Table 29 : Selected Protein Drugs Produced, by Transgenic Animals, Plants, and Microorganisms
• Table 30 : Selected Protein Drugs Made, by Cell Culture
• Table 31 : Number and Distribution of Persons Aged 60+, by Region, 2019 and 2050
• Table 32 : Global Pipeline Molecules, by Type, Through 2021
• Table 33 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
• Table 34 : Percentage of Major Proteins Present in Different Fractions After Cohn's Fractionation Method
• Table 35 : Global Market for Bioengineered Protein Drugs, by Disease, Through 2027
• Table 36 : Global Market for Bioengineered Protein Drugs, by Region, Through 2027
• Table 37 : Newly Approved Monoclonal Antibodies (mAbs), January 2021-December 2022
• Table 38 : Newly Approved Peptide Hormones and Drugs, January 2021-December 2022
• Table 39 : Newly Approved Vaccines, January 2021-December 2022
• Table 40 : Vaccine Candidates in Clinical Phase, January 2021-December 2022
• Table 41 : Newly Approved Blood Factors, January 2021-December 2022
• Table 42 : Newly Approved Peptide Antibiotics, January 2021-December 2022
• Table 43 : Newly Approved Therapeutic Enzymes, January 2021-December 2022
• Table 44 : Newly Approved Cytokines, January 2021-December 2022
• Table 45 : Newly Approved Fusion Protein, January 2021-December 2022
• Table 46 : Selected Bi-Specific Antibodies in Phase 3 Clinical Trials, 2023
• Table 47 : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
• Table 48 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
• Table 49 : Objective Signs of Pain
• Table 50 : Prevalence of Chronic Pain in Older Adults, by Site
• Table 51 : Opioid Lawsuit Settlements
• Table 52 : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
• Table 53 : FDA Pain Management Drug Approvals, 2020-2023
• Table 54 : Pain Management Major Drugs, by Company
• Table 55 : Emerging Pain Therapeutics
• Table 56 : Global Market for Pain Management Pharmaceuticals, by Product, Through 2028
• Table 57 : Global Market for Pain Management Devices, by Type, Through 2028
• Table 58 : Global Market for Pain Management Drugs and Devices, by Application, Through 2028
• Table 59 : Cumulative Volumes of Hip and Knee Procedures, 2012-2021
• Table 60 : Neuropathic Pain Medication
• Table 61 : Cancer Pain Medication
• Table 62 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
• Table 63 : ESG Ranking of Major Pharma Players for Pain Therapeutics, 2022
• Table 64 : ESG Rankings for Major Pain Management Drug and Device Companies, 2023*
• Table 65 : ESG: Environmental Overview
• Table 66 : ESG: Social Overview
• Table 67 : ESG: Governance Overview

List of Figures

• Figure 1 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
• Figure 2 : Global Market for Anti-obesity Drugs, by Drug Type, 2021-2028
• Figure 3 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
• Figure 4 : Global Market Shares of Anti-obesity Drugs, by Region, 2021-2028
• Figure 5 : Global Market Shares of Drugs of Abuse Testing, by Region, 2021
• Figure 6 : Annual Self-reported Alcohol-impaired Driving Episodes Among U.S. Adults, 2010-2020
• Figure 7 : Legal Adult-Use Cannabis Sales Worldwide, 2020-2025*
• Figure 8 : Global Market Shares of Drugs of Abuse Testing, by Region, 2021
• Figure 9 : Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
• Figure 10 : Global Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021
• Figure 11 : Global Market Shares of Bioengineered Protein Drugs, by Disease, 2021
• Figure 12 : Snapshot of Global Market for Bioengineered Protein Drugs, by Region
• Figure 13 : Global Market Shares of Bioengineered Protein Drugs, by Region, 2021
• Figure 14 : NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
• Figure 15 : Share of NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
• Figure 16 : Global Market for Pain Management Drugs and Devices, by Product, 2020-2028
• Figure 17 : Global Market for Pain Management Drugs and Devices, by Region, 2020-2028
• Figure 18 : Pain Management Techniques
• Figure 19 : Pain Management Drugs and Devices: Market Dynamics
• Figure 20 : Common Chronic Pain: Reasons
• Figure 21 : Cancer Incidence, by Region, 2020 vs. 2040
• Figure 22 : Percentage of Global Population Above 65 Years, 2018-2022
• Figure 23 : Global Market Shares of Pain Management Drugs and Devices , by Product, 2022
• Figure 24 : Global Market Shares of Pain Management Pharmaceuticals, by Product, 2022
• Figure 25 : Global Market Shares of Pain Management Devices, by Type, 2022
• Figure 26 : Global Market Shares of Pain Management Drugs and Devices, by Application, 2022
• Figure 27 : Classification of Neuropathic Pain
• Figure 28 : Causes of Cancer Pain
• Figure 29 : Burn Pain Management Approach
• Figure 30 : Global Market Shares of Pain Management Drugs and Devices, by Region, 2022
• Figure 31 : ESG Pillars
• Figure 32 : Advantages of ESG for Companies
• Figure 33 : ESG-Adoption Level across Industries
• Figure 34 : Hospitals: Sustainability Priorities
• Figure 35 : Novartis: ESG Rating
• Figure 36 : Novartis: Major ESG Activities, 2022

The global market for drugs of abuse (DOA) testing is estimated to increase from $5.2 billion in 2022 to reach $8.1 billion by 2027, at a compound annual growth rate (CAGR) of 9.3% from 2022 through 2027.

The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.

The global market for pain management drugs and devices is expected to increase from $84.6 billion in 2023 to $109.9 billion by the end of 2028, with a compound annual growth rate (CAGR) of 5.4% during the forecast period of 2023-2028.

Research Review Scope

The pharmaceutical market is one of the biggest industries in the world, and it is continuously growing. Continuous and ongoing research and development are happening in the pharmaceutical market, with the entry of new drugs and the performance of the current drugs. However, a drug's entry into the market takes around 12-13 years, but the market for existing drugs keeps soaring, which is why the pharmaceutical market keeps growing.

Research and development play a vital role in the growth of the pharmaceutical market, driven by technological and scientific advancements, especially in cell and gene therapies. The market is affected by stringent regulatory and reimbursement policies and escalating research and development costs. Artificial intelligence can be considered crucial with its usage in multiple fields of pharmaceuticals, such as drug discovery, clinical trials, drug screening, personalized medicine, supply chain management, regulatory compliance, pharmacovigilance, and marketing insights. Generative AI tools help accelerate drug discovery by automating tedious and time-consuming tasks.

Research Reviews from BCC Research provide market professionals with concise market coverage within a specific research category. This 2023 Pharmaceuticals Research Review provides a sampling of the type of quantitative market information, analysis, and guidance that BCC Research has been developing since its inception in 1971 to help its customers make informed business decisions. This Research Review includes highlights and excerpts from the following reports published by BCC Research in 2023:

PHM281A Anti Obesity Drugs Market

• PHM013J Drugs of Abuse Testing: Technologies and Global Markets
• BIO009H Global Markets for Bioengineered Protein Drugs
• HLC026G The Global Market for Pain Management Drugs and Devices

After you survey the excerpts in this Research Review, we encourage you to follow up on these topics by checking out the full market research reports associated with each topic. BCC Research looks forward to serving your market intelligence needs in the future.

Table of Contents

Chapter 1 Foreword

• Research Review Scope

Chapter 2 Global Market for Anti-obesity Drugs (PHM281A)

• Anti-obesity Drugs
• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• Market Outlook
• Market Summary
• Market Overview of Anti-obesity Drugs
• Definitions of Adult Obesity and Overweight
• Rising Prevalence of Obesity
• Impact of Obesity on Global Economy
• Increasing Awareness Regarding Obesity
• Global Market for Anti-obesity Drugs, by Type
• Prescription Drugs
• Over-the-Counter Anti-obesity Drugs
• Global Market for Anti-obesity Drugs, by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Market for Anti-obesity Drugs, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World
• ESG Developments of Anti-obesity Drugs
• Importance of ESG in Anti-obesity Drugs Industry
• ESG Pillars in the Anti-obesity Drug Industry
• ESG Ratings and Metrics: Understanding the Data
• ESG Practices in the Anti-obesity Drug Industry
• Concluding Remarks from BCC

Chapter 3 Drugs of Abuse Testing: Technologies and Global Markets (PHM013J)

• Drugs of Abuse Testing
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Summary and Highlights
• Market and Technology Background of Drugs of Abuse Testing
• Overview
• Testing Technologies
• Single Tests vs. Multiparameter Tests
• DOA Screening
• Porter's Five Forces Analysis of Drugs of Abuse Testing
• Market Dynamics of Drugs of Abuse Testing
• Market Drivers
• Market Restraints
• Market Opportunities
• Regulatory Scenario of Drugs of Abuse Testing
• North America
• South America
• Central America and the Caribbean
• Europe
• Asia-Pacific
• Global Drugs of Abuse Testing Market, by Drug Type
• Alcohol
• Amphetamine and Methamphetamine
• Cannabis/Marijuana
• Cocaine
• Opioids
• Others
• Global Drugs of Abuse Testing Market, by End User
• Drug Testing Laboratories
• Hospitals
• Workplaces
• Others
• Market Breakdown of Drugs of Abuse Testing, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 4 Global Markets for Bioengineered Protein Drugs (BIO009H)

• Bioengineered Protein Drugs
• Study Goals and Objectives
• Scope of This Report
• Market Summary
• Market and Technology Background of Bioengineered Protein Drugs
• Protein Drugs Overview
• Bioengineered Protein Drugs
• Manufacturing Technologies of Bioengineered Protein Drugs
• Fractionation/Extraction from Natural Sources (Human/Animal)
• Microbial Fermentation and Bioreactors
• Transgenics
• Mammalian Cell Culture
• Market Dynamics of Bioengineered Protein Drugs
• Market Driver
• Market Challenges
• Market Breakdown of Bioengineered Protein Drugs by Drug Type
• Overview
• Monoclonal Antibodies (mAbs)
• Peptide Hormones
• Vaccines
• Fusion Proteins
• Blood Factors
• Peptide Antibiotics
• Cytokines
• Therapeutic Enzymes
• Market Breakdown of Bioengineered Protein Drugs, by Disease
• Overview
• Market Breakdown of Bioengineered Protein Drugs, by Region
• North America Market Revenue, by Drug Type
• Europe Market Revenue, by Drug Type
• Emerging Markets Revenue, by Drug Type
• Regulatory Aspects and New Approvals of Bioengineered Protein Drugs Market
• New Approvals
• Emerging Trends/Upcoming Technologies in the Market
• Bi- and Multi-Specific Antibodies
• Key Trends in Biopharmaceutical Industry

Chapter 5 Global Market for Pain Management Drugs and Devices (HLC026G)

• Pain Management Drugs and Device
• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• Market Outlook
• Market Summary
• Highlights of the Market for Pain Management Drugs and Devices
• Market Overview of Pain Management Drugs and Device
• History of Pain and Pain Treatment
• The Perception of Pain
• Types of Pain
• Assessment of Pain
• How Pain is Diagnosed
• How Pain is Treated
• Market Dynamics of Pain Management Drugs and Device
• Market Drivers
• Market Restraints
• Market Challenges
• Market Breakdown of Pain Management Drugs and Device, by Product
• Pharmaceuticals
• Pain Management Devices
• Market Breakdown of Pain Management Drugs and Device, by Application
• Musculoskeletal Pain
• Post-operative Pain
• Neuropathic Pain
• Cancer Pain
• Migraine/Headache
• Other Applications
• Market Breakdown of Pain Management Drugs and Device, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World
• ESG Development of Pain Management Drugs and Device
• Introduction to ESG
• Sustainability in the Pain Management Drugs and Devices Industry: An ESG Perspective
• Case Study
• Concluding Remarks from BCC
• Emerging Technologies of Pain Management Drugs and Device
• Overview
• Technology Advancements in Opioid Drugs
• Technology Advancements in Non-narcotic Drugs
• Technology Advancements in Neuromodulation Devices
• Technology Advancements in Infusion Pumps
• Trends in Pain Management

Chapter 6 Appendix

• Methodology
• Analyst's Credentials